Howard is an Entrepreneur-in-Residence on the Frazier Life Sciences team with over 30 years of experience as a cardiologist and therapeutic research and clinical development executive.
Howard joined Frazier in January 2016 and is currently Chief Medical Officer at Frazier portfolio company Cirius Therapeutics, which is developing the next-generation insulin sensitizer for the treatment of nonalcoholic steatohepatitis (NASH).
Howard previously served as Chief Medical Officer of Sorbent Therapeutics, Sequel Pharmaceuticals, and NovaCardia. Prior to NovaCardia, he held executive positions at Molecular Biosystems and Alliance Pharmaceutical. In these positions, he oversaw clinical development and regulatory affairs and was instrumental in gaining FDA approval of two cardiovascular imaging agents.
Howard is an adjunct professor of medicine and chair of the board of directors of the François M. Abboud Cardiovascular Research Center at the University of Iowa Carver College of Medicine. He was previously a faculty member of the department of medicine and a clinical professor of medicine at the University of California, San Diego (UCSD).
Howard holds a B.S. from the University of Iowa and an M.D. from the University of Iowa Carver College of Medicine. He completed his residency in internal medicine and clinical fellowship in cardiology at UCSD.
University of Iowa (M.D., B.S.)